IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"?

Atherosclerosis. 2015 May;240(1):161-2. doi: 10.1016/j.atherosclerosis.2015.03.002. Epub 2015 Mar 10.

Authors

Luis Masana¹, Juan Pedro-Botet², Fernando Civeira³

Affiliations

¹ Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, "Sant Joan" University Hospital, Universitat Rovira i Virgili, IISPV, Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Reus, Spain.
² Lipid and Vascular Risk Unit, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain.
³ Head Lipid Unit, Hospital Universitario Miguel Servet, IIS Aragon, Red Cardiovascular Research Network (RIC), Zaragoza, Spain. Electronic address: civeira@unizar.es.

PMID: 25795557
DOI: 10.1016/j.atherosclerosis.2015.03.002

No abstract available

Keywords: Ezetimibe; High-intensity cholesterol-lowering therapy; IMPROVE-IT.

MeSH terms

Anticholesteremic Agents / adverse effects
Anticholesteremic Agents / therapeutic use*
Biomarkers / blood
Cardiovascular Diseases / diagnosis
Cardiovascular Diseases / etiology
Cardiovascular Diseases / prevention & control*
Cholesterol / blood*
Clinical Trials as Topic
Down-Regulation
Drug Therapy, Combination
Evidence-Based Medicine
Ezetimibe / adverse effects
Ezetimibe / therapeutic use*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Hypercholesterolemia / blood
Hypercholesterolemia / complications
Hypercholesterolemia / diagnosis
Hypercholesterolemia / drug therapy*
Practice Guidelines as Topic
Risk Assessment
Risk Factors
Treatment Outcome

Substances

Anticholesteremic Agents
Biomarkers
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cholesterol
Ezetimibe